ArticleMedicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents2026
MRS2339, a cardiac P2X4 receptor nucleotide activator, improves systolic function in heart failure.
Article in Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Growing evidence is highlighting purinergic receptors as therapeutic targets in cardiac diseases. MRS2339, a charged (N)-methanocarba derivative of 2-Cl-adenosine monophosphate, is efficacious in multiple animal models of systolic heart failure with reduced ejection fraction following infarction, pressure overload, calsequestrin overexpression, rapid pacing, and other injuries. In this study, we explored the beneficial mechanisms of this nucleotide analog in dogs with rapid pacing-induced systolic heart failure and in mice with postinfarct ischemic heart failure. In dogs, sustained infusion of the nucleotide analog increased stroke volume, cardiac output, arterial blood pressure, and arterial oxygen level without any vascular effects, suggesting direct cardiac effects of the drug. In the murine model, MRS2339 caused an increase in myocardial cyclic GMP level, a known cardioprotective second messenger in wild type mice, but no effects in P2X4 receptor knockout mice. Previous data showed that MRS2339 was able to elicit a current in adult mouse cardiomyocytes. The present data showed that MRS2339 could not stimulate a current through rat homomeric P2X4 receptors expressed in HEK293 cells. While the composition of endogenous cardiomyocyte P2X receptors is not known, P2X4 receptors in the heart appear necessary for MRS2339-induced cyclic GMP increase. Our findings support a novel cardiac P2X 4 receptor-mediated cyclic GMP enhancement by MRS2339 as a cellular mechanism of action in heart failure. Stimulating cardiac P2X receptors with increased cyclic GMP level to yield hemodynamic improvement is a potential new therapeutic target in heart failure.
Indexed as
Identifiers
42446539What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.